source
- Roche reports updated eye drug data and FDA filing acceptance, targets July 2027 decisionRoche Genentech has presented new data from its eye disease trials, a year after a mixed Phase 3 readout, and noted that the FDA has accepted its filing for vamikibart with a decision slated for Ju…
- Strategic CDMO partnerships shift from transactional to collaborative, emphasizing risk sharing and regulatory expertiseCDMO-sponsor relationships are moving away from simple outsourcing toward deeper strategic collaboration. Companies now look for partners who share risk, understand regulatory requirements, and pro…